E2F4 and breast cancer: We validate our framework with three widely used clinical biomarkers (Oncotype DX, MammaPrint and E2F4) for breast cancer, which we successfully discover those biomarkers have higher accuracy of predictability within a subset of patient with specific clinical or genetic features.